Ipatimup

RESEARCHDIAGNOSTICSTRANSLATIONOUTREACH

Paula Soares

Name: Paula Soares

E-mail: psoares@ipatimup.pt

Curriculum Vitae

Paula Soares

Member of

Consultant of Ipatimup Diagnostics

Researcher of Cancer Signalling & Metabolism

Short CV

Paula Soares, BSc, MSc, PhD, is Assistant Professor of Biopathology at the Medical Faculty of Porto and coordinates the Group of Cancer Biology at the IPATIMUP/Cancer signaling and Metabolism at I3S. She received her Biology degree in Science Faculty, University of Porto and MSc and PhD degrees at the Medical Faculty, University of Porto. Her main research interests include oncobiology of thyroid and other neuroendocrine tumors, mainly addressing the cellular and molecular biology of thyroid tumors. Her team identify BRAF and TERT promoter mutations in thyroid tumors and become one of the world?s most cited group in thyroid carcinogenesis. Besides participating or leading several national and international funded projects, the practical relevance of Paula?s work has allowed her to secure funding and collaborations from several major pharmaceutical companies. She has over 240 papers (including book chapters) in peer-reviewed journals, mainly addressing the cellular and molecular biology of thyroid tumors, with over 8.000 citations and an h-index of 45. She is also a member of numerous scientific committees and evaluation boards and serves on grant review committees and in journal editorial and review boards.

Highlights

Cellular and molecular biology of thyroid tumors

Supervisor of

Adriana Silva, Master Student (theoretical phase)
MSc student

Sofia Macedo, Fellow
PhD Fellowship

Antónia Póvoa, Assistant Professor
External Researcher

Arnaud Paula, Assistant Researcher
Assistant Researcher

Bárbara Ferreira, External Consultant
Research Fellowship (MSc)

Bruno Carvalho, Assistant Professor
Researcher

César Martins, PhD Student
PhD student

Elisabete Rios, PhD Student
PhD student

João Brás, Junior Researcher
Junior Researcher

João Vinagre, Assistant Researcher
Assistant Researcher

Jorge Lima, Researcher

Leandro Miranda-Alves, Visiting Researcher
Visiting Researcher

Lucas Caridade, Research Trainee
Research Trainee

Luís Cardoso, PhD Student
PhD student

Nuno Mendes, Research Technician
Team Member

Raquel Lima, Collaborator
External Consultant

Rui Batista, Collaborator
Visiting Researcher

Rui Martins, Master Student (theoretical phase)
MSc student

Sara Soares, Research Trainee
Research Trainee

Tiago Gaspar, Assistant Professor
External Researcher

Tito Jesus, Junior Researcher
Junior Researcher

PI (running)

Assessing the mitochondrial impact of TERT in thyroid cancer

Caracterização histológica, molecular e proteica dos carcinomas da tireoide avançados, tratados com inibidores de tirosina cinase

Fishing endocrine disruptors contribution to cancer

"Identificação de biomarcadores moleculares de metastização em melanoma cutâneo"

Molecular characterisation of corticotroph adenomas in a Portuguese cohort

PI (closed)

The other faces of telomerase in thyroid cancer: looking beyond tumour immortalization

Molecular subtypes switching in non-invasive and muscle-invasive bladder cancer – the emerging role of biomarker

Diabetes mellitus and oncocytic tumors of thyroid: the mitochondrial connection.

As outras faces da Telomerase: olhando para além da imortalização tumoral

Tackling cancer stem cells: a challenge and an opportunity to advance in anti-cancer therapy (CANCERSTEM)

Is thyroid gland a target of SARS-CoV-2 infection? Early identification and follow-up of thyroid dysfunction in COVID-19 patients

Telomerase promoter mutations-consolidation of a multipurpose biomarker.

Proteinas teloméricas dos linfomas de células T cutâneas: potenciais indicadores de tumorigenicidade.

Telomeric proteins as potential indicators of tumorigenicity in cutaneous lymphomas

Investigação do papel funcional da osteopontina e de suas variantes de splicing alternativo em tumores da tireóide

Alternative oncogenic signalling pathways in medullary thyroid cancer

Microenvironment, metabolism and cancer

Alterações metabólicas e cancro: GRIM-19 um gene do metabolismo celular e um gene supressor tumoral, que poderá ser um target terapêutico interssante

Transcriptional and post-transcriptional mechanisms of LRP1B inactivation in sporadic and familial non-medullary thyroid cancer

Polimorfismos em genes de moléculas pro-inflamatórias e risco de tireoidite de Hashimoto

Desenvolvimento de estudos que identifiquem compostos com propriedades quimioprotectoras da carcinogênese ou com propriedades inibidoras da invasão de células tumorais

Instalação de uma base de dados e banco de tecidos de tumores estromais gastrointestinais e tumores neuroendócrinos (Regist e REGENE)

Genetic alterations thyroid tumours

Oncogenic role of BRAF activation in thyroid carcinogenesis

Is the mTOR pathway relevant in the initiation/progression and/or a putative therapeutic target in melanomas?

Biological Role of BRAF activaction in colon carcinogenesis STI-571/Gleevec as therapeutic agent?

First Author

1. Soares P, Póvoa AA, Melo M, Vinagre J, Máximo V, Eloy C, Cameselle-Teijeiro JM, Sobrinho-Simões M

Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification. Endocrine pathology 32: 44-62, 2021. [Review]

doi: 10.1007/s12022-021-09666-1 PMID: 33651322.

3.9 (*)

2. Martins-Mendes D, Monteiro-Soares M, Boyko EJ, Ribeiro M, Barata P, Lima J, Soares R

The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk. Journal of diabetes and its complications 28: 632-8, 2014. [Article]

doi: 10.1016/j.jdiacomp.2014.04.011 PMID: 24877985.

133

3.0

3. Soares P, Celestino R, Gaspar da Rocha A, Sobrinho-Simões M

Papillary Thyroid Microcarcinoma: How to Diagnose and Manage this Epidemic? International journal of surgical pathology 22: 113-9, 2014. [Article]

doi: 10.1177/1066896913517394 PMID: 24401191.

1.0

4. Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M

Prognostic biomarkers in thyroid cancer. Virchows Archiv : an international journal of pathology 464: 333-46, 2014. [Review]

doi: 10.1007/s00428-013-1521-2 PMID: 24487783.

2.7

5. Celestino R, Lima J, Faustino A, Máximo V, Gouveia A, Vinagre J, Soares P, Lopes JM

A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. Familial cancer 11: 189-94, 2012. [Article]

doi: 10.1007/s10689-011-9499-x PMID: 22160509.

1.9

6. Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, Couto JP, Prazeres H, Eloy C, Máximo V, Sobrinho-Simões M

Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Current genomics 12: 609-17, 2011. [Article]

doi: 10.2174/138920211798120853 PMID: 22654560.

2.4

7. Soares P, Sobrinho-Simões M

Cancer: Small papillary thyroid cancers--is BRAF of prognostic value? Nature reviews. Endocrinology 7: 9-10, 2011. [Editorial Material]

doi: 10.1038/nrendo.2010.213 PMID: 21160471.

10.0

8. Soares P, Sobrinho-Simões M

Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer? Future oncology (London, England) 5: 1225-9, 2009. [Article]

doi: 10.2217/fon.09.81 PMID: 19852736.

9. Soares P, Trovisco V, Rocha AS, Feijão T, Rebocho AP, Fonseca E, Vieira de Castro I, Cameselle-Teijeiro J, Cardoso-Oliveira M, Sobrinho-Simões M

BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv : an international journal of pathology 444: 572-6, 2004. [Article]

doi: 10.1007/s00428-004-1018-0 PMID: 15095090.

2.2

10. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M

BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-80, 2003. [Article]

doi: 10.1038/sj.onc.1206706 PMID: 12881714.

499

6.5

11. Soares P, Máximo V, Sobrinho-Simöes M

Molecular pathology of papillary, follicular and Hürthle cell carcinomas of the thyroid. Arkhiv patologii 65: 45-7, 2003. []

PMID: 15357248.

12. Soares P, Sobrinho-Simões M

Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287-294, 1998. Clinical cancer research : an official journal of the American Association for Cancer Research 5: 3724-5, 1999. [Letter]

PMID: 10589793.

2.9

13. Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simões M

Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? The Journal of pathology 185: 71-8, 1998. [Article]

doi: 10.1002/(SICI)1096-9896(199805)185:1<71::AID-PATH42>3.0.CO;2-S PMID: 9713362.

104

14. Soares P, Berx G, van Roy F, Sobrinho-Simões M

E-cadherin gene alterations are rare events in thyroid tumors. International journal of cancer 70: 32-8, 1997. [Article]

PMID: 8985087.

3.4

15. Soares P, dos Santos NR, Seruca R, Lothe RA, Sobrinho-Simões M

Benign and malignant thyroid lesions show instability at microsatellite loci. European journal of cancer (Oxford, England : 1990) 33: 293-6, 1997. [Article]

PMID: 9135503.

16. Soares P, Sobrinho-Simões M

Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Pathology, research and practice 191: 304-17, 1995. [Article; Proceedings Paper]

PMID: 7479347.

17. Soares P, Cameselle-Teijeiro J, Sobrinho-Simões M

Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology 24: 205-10, 1994. [Article]

PMID: 8200621.

18. Soares P, Sambade C, Sobrinho-Simões M

Expression of C-erb B2 in tumours and tumour-like lesions of the thyroid. International journal of cancer 56: 459-61, 1994. [Letter]

PMID: 7906256.

19. Soares P, Sobrinho-Simöes M

Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. Cancer 73: 2879-81, 1994. [Letter]

PMID: 7910779.

Senior Author

1. Macedo S, Pestana A, Santos L, Neves C, Guimarães S, Duarte-Neto A, Dolhnikoff M, Saldiva P, Alves G, Oliveira R, Cabanes D, Carneiro F, Sobrinho-Simões M, Soares P

Detection of SARS-CoV-2 infection in thyroid follicular cells from a COVID-19 autopsy series. European thyroid journal 11: ., 2022. [Article]

doi: 10.1530/ETJ-22-0074 PMID: 35900859.

4.1 (*)

2. Boaventura P, Macedo S, Ribeiro F, Jaconiano S, Soares P

Post-COVID-19 Condition: Where Are We Now? Life (Basel, Switzerland) 12: ., 2022. [Review]

doi: 10.3390/life12040517 PMID: 35455008.

3.3 (*)

3. Póvoa AA, Teixeira E, Bella-Cueto MR, Batista R, Pestana A, Melo M, Alves T, Pinto M, Sobrinho-Simões M, Maciel J, Soares P

Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma. Cancers 13: ., 2021. [Article]

doi: 10.3390/cancers13092048 PMID: 33922635.

6.6 (*)

4. Pópulo H, Domingues B, Sampaio C, Lopes JM, Soares P

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. Journal of experimental pharmacology 13: 521-535, 2021. [Article]

doi: 10.2147/JEP.S297831 PMID: 34079392.

5. Batista R, Vinagre N, Meireles S, Vinagre J, Prazeres H, Leão R, Máximo V, Soares P

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. Diagnostics (Basel, Switzerland) 10: ., 2020. [Review]

doi: 10.3390/diagnostics10010039 PMID: 31941070.

2.5 (*)

6. Batista R, Lima L, Vinagre J, Pinto V, Lyra J, Máximo V, Santos L, Soares P

TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. International journal of molecular sciences 21: ., 2020. [Article]

doi: 10.3390/ijms21030947 PMID: 32023888.

4.6 (*)

7. Ferreira LB, Gimba E, Vinagre J, Sobrinho-Simões M, Soares P

Molecular Aspects of Thyroid Calcification. International journal of molecular sciences 21: ., 2020. [Review]

doi: 10.3390/ijms21207718 PMID: 33086487.

4.6 (*)

8. Sieverink CA, Batista RPM, Prazeres HJM, Vinagre J, Sampaio C, Leão RR, Máximo V, Witjes JA, Soares P

Clinical Validation of a Urine Test (Uromonitor-V2®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. Diagnostics (Basel, Switzerland) 10: ., 2020. [Article]

doi: 10.3390/diagnostics10100745 PMID: 32987933.

2.5 (*)

9. Póvoa AA, Teixeira E, Bella-Cueto MR, Melo M, Oliveira MJ, Sobrinho-Simões M, Maciel J, Soares P

Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma. Cancers 12: ., 2020. [Article]

doi: 10.3390/cancers12113186 PMID: 33138175.

6.1 (*)

10. Pestana A, Batista R, Celestino R, Canberk S, Sobrinho-Simões M, Soares P

Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours. Cancers 12: ., 2020. [Article]

doi: 10.3390/cancers12071846 PMID: 32659948.

6.1 (*)

11. Campos MA, Macedo S, Fernandes MS, Pestana A, Pardal J, Batista R, Vinagre J, Sanches A, Baptista A, Lopes JM, Soares P

Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas. Genes 11: ., 2020. [Article]

doi: 10.3390/genes11070751 PMID: 32640663.

3.8 (*)

12. Dionísio de Sousa IJ, Marques DS, Príncipe C, Portugal RV, Canberk S, Prazeres H, Lopes JM, Gimba ERP, Lima RT, Soares P

Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer. Diagnostics (Basel, Switzerland) 10: ., 2020. [Article]

doi: 10.3390/diagnostics10080525 PMID: 32731632.

2.5 (*)

13. Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceição P, Sismeiro A, Leão R, Gomes A, Furriel F, Oliveira C, Torres JN, Eufrásio P, Azinhais P, Almeida F, Gonzalez ER, Bidovanets B, Ecke T, Stinjs P, Pascual ÁS, Abdelmalek R, Villafruela A, Beardo-Villar P, Fidalgo N, Öztürk H, Gonzalez-Enguita C, Monzo J, Lopes T, Álvarez-Maestro M, Servan PP, De La Cruz SMP, Perez MPS, Máximo V, Soares P

Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. Frontiers in genetics 10: 1237, 2019. [Article]

doi: 10.3389/fgene.2019.01237 PMID: 31921291.

3.5 (*)

14. Campos MA, Macedo S, Fernandes M, Pestana A, Pardal J, Batista R, Vinagre J, Sanches A, Baptista A, Lopes JM, Soares P

TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology 80: 660-669.e6, 2019. [Article]

doi: 10.1016/j.jaad.2018.08.032 PMID: 30165166.

8.3

15. Santos LR, Durães C, Ziros PG, Pestana A, Esteves C, Neves C, Carvalho D, Bongiovanni M, Renaud CO, Chartoumpekis DV, Habeos IG, Simões MS, Soares P, Sykiotis GP

Interaction of Genetic Variations in NFE2L2 and SELENOS Modulates the Risk of Hashimoto's Thyroiditis. Thyroid : official journal of the American Thyroid Association 29: 1302-1315, 2019. [Article]

doi: 10.1089/thy.2018.0480 PMID: 31426718.

5.2

16. Tavares C, Coelho MJ, Eloy C, Melo M, da Rocha AG, Pestana A, Batista R, Ferreira LB, Rios E, Selmi-Ruby S, Cavadas B, Pereira L, Sobrinho Simões M, Soares P

NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocrine connections 7: 78-90, 2018. [Article]

doi: 10.1530/EC-17-0302 PMID: 29298843.

3.0 (*)

17. Celestino R, Nome T, Pestana A, Hoff AM, Gonçalves AP, Pereira L, Cavadas B, Eloy C, Bjøro T, Sobrinho-Simões M, Skotheim RI, Soares P

CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. BMC cancer 18: 68, 2018. [Article]

doi: 10.1186/s12885-017-3948-3 PMID: 29321030.

3.3 (*)

18. Tavares C, Eloy C, Melo M, Gaspar da Rocha A, Pestana A, Batista R, Bueno Ferreira L, Rios E, Sobrinho Simões M, Soares P

mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. International journal of molecular sciences 19: ., 2018. [Article]

doi: 10.3390/ijms19051448 PMID: 29757257.

3.7 (*)

19. Sousa I, Rodrigues F, Prazeres H, Lima RT, Soares P

Liposomal therapies in oncology: does one size fit all? Cancer chemotherapy and pharmacology 82: 741-755, 2018. [Review]

doi: 10.1007/s00280-018-3668-7 PMID: 30116847.

2.8 (*)

20. Ferreira LB, Lima RT, Bastos ACSDF, Silva AM, Tavares C, Pestana A, Rios E, Eloy C, Sobrinho-Simões M, Gimba ERP, Soares P

OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines. International journal of molecular sciences 19: ., 2018. [Article]

doi: 10.3390/ijms19102990 PMID: 30274371.

3.7 (*)

21. Boaventura P, Durães C, Mendes A, Costa NR, Chora I, Ferreira S, Araújo E, Lopes P, Rosa G, Marques P, Tavares S, Chaves V, Bettencourt P, Oliveira I, Costa F, Ramos I, Teles MJ, Guimarães JT, Sobrinho-Simões M, Soares P

Is Low-Dose Radiation Exposure a Risk Factor for Atherosclerotic Disease? Radiation research 189: 418-424, 2018. [Article]

doi: 10.1667/RR14942.1 PMID: 29461943.

2.5 (*)

22. Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. The Journal of clinical endocrinology and metabolism 102: 1898-1907, 2017. [Article]

doi: 10.1210/jc.2016-2785 PMID: 28323937.

5.8

23. Pestana A, Vinagre J, Sobrinho-Simões M, Soares P

TERT biology and function in cancer: beyond immortalisation. Journal of molecular endocrinology 58: R129-R146, 2017. [Review]

doi: 10.1530/JME-16-0195 PMID: 28057768.

3.3

24. Rodrigues AC, Penna G, Rodrigues E, Castro P, Sobrinho-Simões M, Soares P

The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications. Current genomics 18: 244-254, 2017. [Review]

doi: 10.2174/1389202918666170105094459 PMID: 28659720.

2.2

25. Pópulo H, Nunes B, Sampaio C, Batista R, Pinto MT, Gaspar TB, Miranda-Alves L, Cai RZ, Zhang XY, Schally AV, Sobrinho-Simões M, Soares P

Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Hormones & cancer 8: 314-324, 2017. [Article]

doi: 10.1007/s12672-017-0307-4 PMID: 28924876.

2.6

26. Boaventura P, Batista R, Pestana A, Reis M, Mendes A, Eloy C, Sobrinho-Simões M, Soares P

TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation. European journal of endocrinology 176: 49-55, 2017. [Article]

doi: 10.1530/EJE-16-0740 PMID: 27760791.

4.3

27. Cappagli V, Potes CS, Ferreira LB, Tavares C, Eloy C, Elisei R, Sobrinho-Simões M, Wookey PJ, Soares P

Calcitonin receptor expression in medullary thyroid carcinoma. PeerJ 5: e3778, 2017. [Article]

doi: 10.7717/peerj.3778 PMID: 28929017.

2.1

28. Pópulo H, Batista R, Sampaio C, Pardal J, Lopes JM, Soares P

SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. PloS one 12: e0180392, 2017. [Article]

doi: 10.1371/journal.pone.0180392 PMID: 28662141.

2.8

29. Amorim JP, Santos G, Vinagre J, Soares P

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes 7: 1, 2016. [Review]

doi: 10.3390/genes7090066 PMID: 27657132.

3.6

30. Penna GC, Vaisman F, Vaisman M, Sobrinho-Simões M, Soares P

Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes. Cytogenetic and genome research 150: 194-207, 2016. [Review]

doi: 10.1159/000456576 PMID: 28231576.

1.4

31. Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, Gimba ER, Soares P

Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget 7: 52003-52016, 2016. [Article]

doi: 10.18632/oncotarget.10468 PMID: 27409830.

5.2

32. Ferreira LB, Eloy C, Pestana A, Lyra J, Moura M, Prazeres H, Tavares C, Sobrinho-Simões M, Gimba E, Soares P

Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. European journal of endocrinology 174: 551-61, 2016. [Article]

doi: 10.1530/EJE-15-0577 PMID: 26811408.

4.1

33. Vinagre J, Nabais J, Pinheiro J, Batista R, Oliveira RC, Gonçalves AP, Pestana A, Reis M, Mesquita B, Pinto V, Lyra J, Cipriano MA, Ferreira MG, Lopes JM, Sobrinho-Simões M, Soares P

TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. Scientific reports 6: 29714, 2016. [Article]

doi: 10.1038/srep29714 PMID: 27411289.

4.3

34. Boaventura P, Durães C, Mendes A, Costa NR, Chora I, Ferreira S, Araújo E, Lopes P, Rosa G, Marques P, Bettencourt P, Oliveira I, Costa F, Ramos I, Teles MJ, Guimarães JT, Sobrinho-Simões M, Soares P

IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort. PloS one 11: e0163474, 2016. [Article]

doi: 10.1371/journal.pone.0163474 PMID: 27662210.

2.8

35. Tavares C, Coelho MJ, Melo M, da Rocha AG, Pestana A, Batista R, Salgado C, Eloy C, Ferreira L, Rios E, Sobrinho-Simões M, Soares P

pmTOR is a marker of aggressiveness in papillary thyroid carcinomas. Surgery 160: 1582-1590, 2016. [Article]

doi: 10.1016/j.surg.2016.06.050 PMID: 27574774.

3.9

36. Melo M, da Rocha AG, Vinagre J, Sobrinho-Simões M, Soares P

Coexistence of TERT Promoter and BRAF Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33: 667-8, 2015. [Letter]

doi: 10.1200/JCO.2014.59.4614 PMID: 25605839.

21.0

37. Pópulo H, Caldas R, Lopes JM, Pardal J, Máximo V, Soares P

Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. Expert opinion on therapeutic targets 19: 733-45, 2015. [Article]

doi: 10.1517/14728222.2015.1045416 PMID: 25976231.

4.8

38. Pópulo H, Lopes JM, Sobrinho-Simões M, Soares P

RE: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. Journal of the National Cancer Institute 107: 1, 2015. [Letter]

doi: 10.1093/jnci/djv049 PMID: 25755155.

11.4

39. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Máximo V, Sobrinho-Simões M, Soares P

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. The Journal of clinical endocrinology and metabolism 99: E754-65, 2014. [Article]

doi: 10.1210/jc.2013-3734 PMID: 24476079.

374

6.2

40. Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimarães I, Manuel Lopes J, Sobrinho-Simões M, Soares P

TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. The Journal of investigative dermatology 134: 2251-7, 2014. [Article]

doi: 10.1038/jid.2014.163 PMID: 24691053.

7.2

41. Vinagre J, Pinto V, Celestino R, Reis M, Pópulo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, Máximo V, Sobrinho-Simões M, Soares P

Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Archiv : an international journal of pathology 465: 119-33, 2014. [Review]

doi: 10.1007/s00428-014-1608-4 PMID: 25048572.

2.7

42. Santos LR, Durães C, Mendes A, Prazeres H, Alvelos MI, Moreira CS, Canedo P, Esteves C, Neves C, Carvalho D, Sobrinho-Simões M, Soares P

A Polymorphism in the Promoter Region of the Selenoprotein S Gene (SEPS1) Contributes to Hashimoto's Thyroiditis Susceptibility. The Journal of clinical endocrinology and metabolism 99: E719-23, 2014. [Article]

doi: 10.1210/jc.2013-3539 PMID: 24471570.

6.2

43. Durães C, Moreira CS, Alvelos I, Mendes A, Santos LR, Machado JC, Melo M, Esteves C, Neves C, Sobrinho-Simões M, Soares P

Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease. PloS one 9: e105492, 2014. [Article]

doi: 10.1371/journal.pone.0105492 PMID: 25127106.

3.2

44. Lyra J, Vinagre J, Batista R, Pinto V, Prazeres H, Rodrigues F, Eloy C, Sobrinho-Simões M, Soares P

mTOR activation in medullary thyroid carcinoma with RAS mutation. European journal of endocrinology 171: 633-40, 2014. [Article]

doi: 10.1530/EJE-14-0389 PMID: 25163725.

4.1

45. Boaventura P, Pereira D, Mendes A, Batista R, da Silva AF, Guimarães I, Honavar M, Teixeira-Gomes J, Lopes JM, Máximo V, Soares P

Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. Journal of dermatological science 73: 31-9, 2014. [Article]

doi: 10.1016/j.jdermsci.2013.09.002 PMID: 24091058.

3.4

46. Boaventura P, Pereira D, Mendes A, Teixeira-Gomes J, Sobrinho-Simões M, Soares P

Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950-1963). Virchows Archiv : an international journal of pathology 465: 445-52, 2014. [Article]

doi: 10.1007/s00428-014-1644-0 PMID: 25146169.

2.7

47. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simões M, Lima J, Máximo V, Soares P

Frequency of TERT promoter mutations in human cancers. Nature communications 4: 2185, 2013. [Article]

doi: 10.1038/ncomms3185 PMID: 23887589.

649

10.7

48. Melo M, Costa G, Ribeiro C, Carrilho F, Martins MJ, da Rocha AG, Sobrinho-Simões M, Carvalheiro M, Soares P

Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later. The Journal of clinical endocrinology and metabolism 98: 4364-72, 2013. [Article]

doi: 10.1210/jc.2013-2267 PMID: 24037891.

6.3

49. Alvelos MI, Vinagre J, Fonseca E, Barbosa E, Teixeira-Gomes J, Sobrinho-Simões M, Soares P

MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. European journal of endocrinology 168: 119-28, 2013. [Article]

doi: 10.1530/EJE-12-0327 PMID: 23093699.

3.7

50. Pópulo H, Tavares S, Faustino A, Nunes JB, Lopes JM, Soares P

GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ 1: e104, 2013. [Article]

doi: 10.7717/peerj.104 PMID: 23904987.

51. Boaventura P, Pereira D, Celestino R, Mendes A, Nakasawa T, Teixeira-Gomes J, Sobrinho-Simões M, Soares P

Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment. European journal of endocrinology 169: 673-679, 2013. [Article]

doi: 10.1530/EJE-13-0543 PMID: 23966419.

3.7

52. Prazeres H, Salgado C, Duarte C, Soares P

LRP1B (low density lipoprotein receptor-related protein 1B) Atlas Genet Cytogenet Oncol Haematol ., 2013. []

53. Melo M, Costa G, Carrilho F, Soares P

Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas Clinical Management of Thyroid Cancer 78-92, 2013. []

54. Pópulo H, Lopes JM, Soares P

The mTOR Signalling Pathway in Human Cancer. International journal of molecular sciences 13: 1886-918, 2012. [Review]

doi: 10.3390/ijms13021886 PMID: 22408430.

583

2.5

55. Faustino A, Couto JP, Pópulo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simões M, Soares P

mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. The Journal of clinical endocrinology and metabolism 97: E1139-49, 2012. [Article]

doi: 10.1210/jc.2011-2748 PMID: 22549934.

6.4

56. Couto JP, Almeida A, Daly L, Sobrinho-Simões M, Bromberg JF, Soares P

AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines. PloS one 7: e46869, 2012. [Article]

doi: 10.1371/journal.pone.0046869 PMID: 23056499.

3.7

57. Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, Gomes D, Cameselle-Teijeiro J, Vidal A, Martins TC, Sobrinho-Simões M, Soares P

Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 30: 1302-17, 2011. [Article]

doi: 10.1038/onc.2010.512 PMID: 21057533.

6.4

58. Pópulo H, Vinagre J, Lopes JM, Soares P

Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. The British journal of ophthalmology 95: 715-9, 2011. [Article]

doi: 10.1136/bjo.2009.174417 PMID: 20805136.

2.9

59. Goncalves AP, Videira A, Maximo V, Soares P

Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death. Journal of biosciences 36: 639-48, 2011. [Article]

PMID: 21857110.

1.6

60. Prazeres H, Torres J, Rodrigues F, Couto JP, Vinagre J, Sobrinho-Simões M, Soares P

How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. Journal of thyroid research 2011: 678357, 2011. []

doi: 10.4061/2011/678357 PMID: 21765992.

61. Sobrinho-Simões M, Magalhães J, Soares P

Hot topics in papillary thyroid carcinoma. International journal of surgical pathology 18: 190S-193S, 2010. [Article; Proceedings Paper]

doi: 10.1177/1066896910370882 PMID: 20484289.

1.1

62. Sobrinho-Simões M, Máximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J, Soares P

Intragenic mutations in thyroid cancer. Endocrinology and metabolism clinics of North America 37: 333-62, viii, 2008. [Review]

doi: 10.1016/j.ecl.2008.02.004 PMID: 18502330.

2.1

63. Rocha AS, Marques R, Bento I, Soares R, Magalhães J, de Castro IV, Soares P

Thyroid hormone receptor beta mutations in the 'hot-spot region' are rare events in thyroid carcinomas. The Journal of endocrinology 192: 83-6, 2007. [Article]

doi: 10.1677/JOE-06-0009 PMID: 17210745.

2.6

64. Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P

Molecular pathology of well-differentiated thyroid carcinomas. Virchows Archiv : an international journal of pathology 447: 787-93, 2005. [Review]

doi: 10.1007/s00428-005-0065-5 PMID: 16189702.

2.2

65. Rocha AS, De Wever O, Moreira S, Costa MJ, Vandekerckhove J, Mareel M, Soares P

Mutated E-cadherin: genomic and functional characterization in thyroid cells from the KAT family. Thyroid : official journal of the American Thyroid Association 14: 902-9, 2004. [Article]

doi: 10.1089/thy.2004.14.902 PMID: 15671768.

2.4

66. Sobrinho-Simões M, Sambade C, Fonseca E, Soares P

Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. International journal of surgical pathology 10: 123-31, 2002. [Article]

PMID: 12075405.

0.7

67. Preto A, Reis-Filho JS, Ricardo S, Soares P

P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathology, research and practice 198: 449-54, 2002. [Article]

PMID: 12234063.

0.9

@ 2014 Ipatimup Institute of Molecular Pathology and Immunology of the University of Porto